Reader response: Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Abstract

The Academy must be commended for its update summary on mild cognitive impairment (MCI).1 Petersen et al.1 utilized the robust methodology of evidence classification criteria and recommendations were graded and clear to the reader: “Clinicians may choose not to offer cholinesterase inhibitors (Level B); if offering, they must first discuss lack of evidence (Level A).”